Advera Care provides accredited peptide therapy education and continuing medical education (CME) for licensed healthcare professionals.
Our educational content explores peptide science, physiology, clinical evidence, safety, patient evaluation, regulatory considerations, and the clinical application of peptide therapy.
Through videos, webinars, and our accredited Peptide Therapy in Clinical Practice CME program, we help clinicians understand not only how peptides are being used, but how they work, what the research supports, and how to evaluate emerging therapies responsibly.
Topics include metabolic peptides, growth hormone peptides, regenerative peptides, peptide research, 503A compounding and regulatory updates, and evidence-informed clinical decision-making.
Advera Care exists to help healthcare professionals build a stronger foundation in peptide therapy and help raise the standard of clinician education in this rapidly developing field.
Advera Care
I think “99% pure” is one of those numbers that can create more confidence than understanding.
When I review a peptide COA, I don't want to see a high percentage and stop there.
I want to know what that percentage actually represents and which analytical method produced it.
Identity and purity are not the same question.
Purity and net peptide content are not the same question.
And a high HPLC purity result doesn't necessarily tell us whether peptide aggregates are present.
Each measurement gives us a different piece of information about the product.
For example, mass spectrometry can help establish whether the molecular mass is consistent with the peptide being tested.
HPLC can separate the intended peptide from related impurities and give us a measure of relative purity.
But that purity percentage doesn't necessarily include water, counterions, or other components contributing to the total powder weight.
And if we're concerned about larger peptide aggregates, we may need a method designed to evaluate those species rather than assuming a standard purity result has answered the question.
That’s why the number on a COA is only useful when you understand what was measured, how it was measured, and what wasn't measured.
When I'm evaluating peptide quality, I’d rather ask:
Was identity confirmed?
Is net peptide content reported?
Was aggregation evaluated?
Where are the sterility and endotoxin results?
A COA should start the quality conversation, not end it.
Save the carousel if you want those questions available the next time you're reviewing testing with a pharmacy.
For clinicians who want to go deeper into peptide quality and clinical application, I cover these concepts inside Peptide Therapy in Clinical Practice.
#peptidetherapy #peptidequality #analyticaltesting #clinicaleducation #medicaleducation
5 days ago | [YT] | 0
View 0 replies
Advera Care
A drug class can give us a biological hypothesis. It cannot give every molecule in that class the same clinical evidence.
That’s what stood out to me when thinking about a question I was asked recently about peptides for pain and Parkinson’s disease.
With pain, I wouldn’t start by asking which peptide is “good for pain.”
I’d start by asking what is actually driving it.
Inflammation? Tissue injury? Nerve damage? Altered pain signaling?
The symptom can look similar while the underlying biology is very different.
Parkinson’s research gives us another version of this problem.
Lixisenatide and exenatide are both GLP-1 receptor agonists, yet their Parkinson’s trials did not produce the same results. Lixisenatide showed less progression of motor disability than placebo over 12 months in the phase 2 LIXIPARK trial, while a later phase 3 trial found no evidence that exenatide slowed Parkinson’s progression.
That’s a useful reminder not to reason from the drug class alone.
What exact molecule was studied?
In what population?
For how long?
And what outcome actually changed?
Those questions are often more useful than asking which peptide is “for” a particular diagnosis.
#peptidetherapy #parkinsonsdisease #glp1 #clinicaleducation #medicaleducation
1 week ago | [YT] | 0
View 0 replies
Advera Care
Clinicians don’t need another hour of someone handing them peptide protocols.
There is already plenty of information telling clinicians what peptide to use, how much to give, and what schedule to follow.
What I think is missing is the education that comes before the protocol.
Can you look at a study and decide how much weight to give it?
Can you separate a promising mechanism from an outcome that has actually been demonstrated in humans?
Can you recognize when the way a peptide was studied doesn’t match the way it’s being discussed clinically?
Those are harder questions.
And they’re a big part of why I created Advera’s free live webinar.
We don’t spend the hour teaching dosing or handing out cheat sheets. We talk about the education gap in peptide therapy, where the field is heading, and why clinicians need more than access to information to make thoughtful decisions.
Because having more information doesn’t automatically create better clinical judgment.
Free live webinar for licensed healthcare professionals
Thursdays • 7:00 PM ET
🔗 go.adveracare.com/lander/
#peptidetherapy #medicaleducation #clinicaleducation #healthcareprofessionals #adveracare
1 month ago | [YT] | 2
View 0 replies
Advera Care
The more I learn about peptide medicine, the less interested I am in pretending we have every answer.
I actually think that’s one of the most important parts of being a good clinician.
Medicine keeps moving.
New research comes out. Our understanding of physiology gets better. Treatments evolve. Sometimes new evidence strengthens what we thought we knew, and sometimes it makes us reconsider it.
Peptide therapy is no different.
There’s a lot of excitement in this field right now, and I share that excitement. But I also believe that if we want peptide medicine to continue moving forward, the standard of education has to move forward with it.
We have to stay curious enough to keep asking questions.
Disciplined enough to go back to the research.
And humble enough to change our thinking when better evidence gives us a reason to.
To me, continuing education isn’t about collecting another credential.
It’s part of the responsibility we take on when patients trust us with their care.
That belief is a big part of why I built Advera, and why I’m so passionate about where peptide education can go from here.
We’re still learning.
And I think that should make us more curious, not less confident.
#PeptideTherapy #MedicalEducation #ContinuingEducation #HealthcareProfessionals #AdveraCare
1 month ago | [YT] | 3
View 0 replies
Advera Care
The future of peptide therapy needs more than protocols.
It needs clinicians who understand where the field is going and why continued education matters.
Join me for a conversation about the education gap in peptide therapy, the direction of the field, and why accredited education has a place in its future.
For physicians, NPs, PAs, nurses, and other healthcare professionals interested in peptide therapy.
Free live webinar every Thursday at 7 PM EST.
🔗 Register through the link: linktr.ee/adveracare/
#PeptideTherapy #ContinuingMedicalEducation #CME #HealthcareProfessionals #AdveraCare
1 month ago (edited) | [YT] | 2
View 0 replies